剂量预测和XZP-5610的药理动力学模拟,NASH治疗的小分子,使用全米缩放和基于生理的药理动力学模型
Lei Zhang1,2,3, Feifei Feng2,3, Xiaohan Wang2
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, China.
这项研究成功地预测了FXR激动剂XZP-5610在人类中的药理动力学 (PK) 和肝脏度,使用全米缩放和PBPK建模. 这些预测支持在早期临床试验中选择安全有效的剂量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
- 毒理学 毒理学 毒理学
背景情况:
- FXR激应剂代表了一个有前途的治疗类.
- 准确预测人类的药理动力学 (PK) 和组织度对于新药开发至关重要.
- XZP-5610是一种新的FXR激活剂,需要在首次在人体 (FIH) 试验中选择剂量.
研究的目的:
- 为了支持FIH试验中的新型FXR激动剂XZP-5610的剂量选择.
- 为了预测中国健康成年人的XZP-5610肝脏度.
- 为了验证药物开发的预测建模方法.
主要方法:
- 在体外和体内研究,以测量关键的抽外参数.
- 从动物数据中预测人类PK参数和剂量.
- 使用动物和临床数据开发和验证一种基于生理学的药理动力学 (PBPK) 模型.
主要成果:
- XZP-5610表现出高透性,低溶解性和广泛的血蛋白结合.
- 预测的人类PK参数:清除量138毫升/分钟,分布量41.8升.
- 预计的剂量:MRSD 0.15毫克,MABEL 2毫克,MTD 3毫克.
- PBPK模型的预测与临床PK数据有很好的一致性.
- 在FIH研究中成功预测XZP-5610肝脏度.
结论:
- 全尺度缩放和PBPK建模是预测人类PK和肝脏FXR激动剂度的有效工具.
- 该研究成功支持XZP-5610 FIH试验的剂量选择.
- 预测建模提高了药物开发早期阶段的效率和安全性.
更多相关视频
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Analysis of Population Pharmacokinetic Data
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
